At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XTL SPDR S&P Telecom ETF
Post-Mkt 05-06 18:26:00 EDT
227.21
-0.31
-0.14%
盘后226.10
-1.11-0.49%
18:10 EDT
High227.64Low224.49Vol105.66K
Open227.60D1 Closing227.52Amplitude1.39%
Mkt Cap778.19MTradable Cap778.19MTotal Shares3.43M
T/O23.86MT/O Rate3.08%Tradable Shares3.43M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline
TIPRANKS  ·  04-29
XTL Biopharmaceuticals to Acquire PsygaBio in All-Stock Deal to Expand Psychedelic Drug Pipeline
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
GlobeNewswire  ·  04-29
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
XTL Biopharmaceuticals trading halted, news pending
TIPRANKS  ·  03-25
XTL Biopharmaceuticals trading halted, news pending
XTL Biopharmaceuticals to Change ADS Ratio
MT Newswires Live  ·  03-21
XTL Biopharmaceuticals to Change ADS Ratio
XTL Biopharmaceuticals to Implement One-for-Four ADS Reverse Split Effective March 25, 2026
TIPRANKS  ·  03-21
XTL Biopharmaceuticals to Implement One-for-Four ADS Reverse Split Effective March 25, 2026
Beyond Air announces termination of NeuroNOS agreement with XTL
TIPRANKS  ·  03-10
Beyond Air announces termination of NeuroNOS agreement with XTL
XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination
TIPRANKS  ·  02-28
XTL Biopharmaceuticals Faces Nasdaq Delisting After “Public Shell” Determination
XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing
TIPRANKS  ·  02-28
XTL Biopharmaceuticals gets delisting letter from Nasdaq, to request hearing
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
GlobeNewswire  ·  02-28
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency
TIPRANKS  ·  01-28
XTL Biopharmaceuticals Advances NeuroNOS Acquisition and Plans $2 Million Private Placement to Address Nasdaq Equity Deficiency
XTL Biopharmaceuticals Faces Subsidiary Insolvency Filing, Reviews $1.5 Million Loan Exposure
TIPRANKS  ·  01-24
XTL Biopharmaceuticals Faces Subsidiary Insolvency Filing, Reviews $1.5 Million Loan Exposure
XTL Biopharmaceuticals Flags Nasdaq Equity Deficiency, Given Deadline to Regain Compliance
TIPRANKS  ·  01-24
XTL Biopharmaceuticals Flags Nasdaq Equity Deficiency, Given Deadline to Regain Compliance
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
GlobeNewswire  ·  01-24
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
ADRs Hold Steady; XTL Biopharmaceuticals Ltd. Climbs 57%
Dow Jones  ·  01-14
ADRs Hold Steady; XTL Biopharmaceuticals Ltd. Climbs 57%
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
GlobeNewswire  ·  01-13
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
XTL Biopharmaceuticals Moves to Acquire NeuroNOS Stake from Beyond Air and Plans $2 Million Private Placement
TIPRANKS  ·  01-13
XTL Biopharmaceuticals Moves to Acquire NeuroNOS Stake from Beyond Air and Plans $2 Million Private Placement

Introduction

Company Name.
SPDR S&P Telecom ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
In seeking to track the performance of the S&P Telecom Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the telecommunications segment of the S&P Total Market Index ("S&P TMI").
Issue price:
--